What Company Will Eli Lilly Buy Next?
Targeting smaller "bolt-on" acquisitions in the range of $1 billion to $5 billion, Eli Lilly (NYSE: LLY) plans to expand its research and development pipeline by acquiring a company roughly every quarter. The company's CFO made these comments during the J.P. Morgan Healthcare Conference as he discussed the company's $1.1 billion purchase of Dermira (NASDAQ: DERM).
Knowing that the big pharmaceutical company is going shopping, some biotech deal makers and investors looking for exits hope their companies will be snapped up next. Here we will explore a few companies that could be on Lilly's shopping list.
Source Fool.com